Skip to main content

Advertisement

SpringerLink
Log in

Monoclonal antibodies in cancer immunotherapy

  • Review
  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

Nowadays, in cancer treatments, immunotherapy which can be classified as a cancer type specific therapy is more popular than non-specific therapy methods such as surgery, radiotherapy and chemotherapy. The main aim of immunotherapy is to enable patients’ immune system to target cancer cells and destroy them. The mainly used treatment methods in cancer immunotherapy are cancer vaccines, adoptive cell therapy, cytokines and monoclonal antibodies. In this review, we discuss the immunotherapy approaches, especially monoclonal antibodies which are mostly used in cancer immunotherapy in clinical applications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Seledtsov VI, Goncharov AG, Seledtsova GV (2015) Multiple-purpose immunotherapy for cancer. Biomed Pharmacother 76:24–29

    Article  CAS  Google Scholar 

  2. Harris TJ, Drake CG (2013) Primer on tumor immunology and cancer immunotherapy. J Immunother Cancer 1:12

    Article  Google Scholar 

  3. Barbaros B, Dikmen M (2015) Kanser İmmünoterapisi. Erciyes Üniversitesi Fen Bilim Enst Derg 31:177–181

    Google Scholar 

  4. Özlük AA, Oytun MG, Günenç D (2017) Kanser immünoterapisi. FNG Bilim Tıp Transpl Derg 2:21–23. https://doi.org/10.5606/fng.transplantasyon.2017.004

    Article  Google Scholar 

  5. Visage M, Joubert A (2010) Minireview: immunotherapy and its role in cancer. Biomed Res 21:377–381

    Google Scholar 

  6. Dimberu PM, Leonhardt RM (2011) Cancer immunotherapy takes a multi-faceted approach to kick the immune system into gear. Yale J Biol Med 84:371–380

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Karlitepe A, Ozalp O, Avci CB (2015) New approaches for cancer immunotherapy. Tumor Biol 36:4075–4078. https://doi.org/10.1007/s13277-015-3491-2

    Article  CAS  Google Scholar 

  8. Farkona S, Diamandis EP, Blasutig IM (2016) Cancer immunotherapy: the beginning of the end of cancer? BMC Med. 14

  9. Papaioannou NE, Beniata OV, Vitsos P et al (2016) Harnessing the immune system to improve cancer therapy. Ann Transl Med 4:261–261. https://doi.org/10.21037/atm.2016.04.01

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Sathyanarayanan V, Neelapu SS (2015) Cancer immunotherapy: strategies for personalization and combinatorial approaches. Mol Oncol 9:2043–2053

    Article  CAS  Google Scholar 

  11. Guo C, Manjili MH, Subjeck JR et al (2013) Therapeutic cancer vaccines. Past, present, and future. Adv Cancer Res. https://doi.org/10.1016/B978-0-12-407190-2.00007-1

    Article  PubMed  PubMed Central  Google Scholar 

  12. Şakalar Ç, İzgi K, Canatan H (2013) Kanser immün terapi ve monoklonal antikorlar. FÜ Sağ Bil Tıp Derg 27:105–110

    Google Scholar 

  13. Mayor M, Yang N, Sterman D et al (2016) Immunotherapy for non-small cell lung cancer: current concepts and clinical trials. Eur J Cardio-Thoracic Surg 49:1324–1333

    Article  Google Scholar 

  14. Neves H, Kwok HF (2015) Recent advances in the field of anti-cancer immunotherapy. BBA Clin 3:280–288

    Article  Google Scholar 

  15. Rini B (2014) Future approaches in immunotherapy. Semin Oncol 41:S30–S40. https://doi.org/10.1053/j.seminoncol.2014.09.005

    Article  CAS  PubMed  Google Scholar 

  16. Mellman I, Coukos G, Dranoff G (2014) Cancer immunotherapy comes of age. Nature 480:480–489. https://doi.org/10.1038/nature10673.Cancer

    Article  Google Scholar 

  17. Bean ES (2000) Polyclonal Antibodies. In: Howard GC, Bethell DR (eds) Methods in antibody production and characterization. CRS Press, Taylor and Francis Group, New York, pp 31–50

    Chapter  Google Scholar 

  18. Kohler H (2000) Superantibodies synergy of innate and acquired immunity. Appl Biochem Biotechnol 83:1. https://doi.org/10.1385/ABAB:83:1-3

    Article  CAS  PubMed  Google Scholar 

  19. Kuhn C, Weiner HL (2016) Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside. Immunotherapy 8:889–906. https://doi.org/10.2217/imt-2016-0049

    Article  CAS  PubMed  Google Scholar 

  20. Pandey S (2010) Hybridoma technology for production of monoclonal antibodies. Int J Pharm Sci Rev Res 1:88–94

    CAS  Google Scholar 

  21. Liu JKH (2014) The history of monoclonal antibody development—progress, remaining challenges and future innovations. Ann Med Surg 3:113–116

    Article  Google Scholar 

  22. Oldham RK, Dillman RO (2008) Monoclonal antibodies in cancer therapy: 25 years of progress. J Clin Oncol 26:1774–1777

    Article  Google Scholar 

  23. Teillaud JL (2012) From whole monoclonal antibodies to single domain antibodies: think small. Methods Mol Biol 911:3–13. https://doi.org/10.1007/978-1-61779-968-6_1

    Article  CAS  PubMed  Google Scholar 

  24. Levene AP, Singh G, Palmieri C (2005) Therapeutic monoclonal antibodies in oncology. J R Soc Med 98:146–152

    Article  CAS  Google Scholar 

  25. Simpson A, Caballero O (2014) Monoclonal antibodies for the therapy of cancer. BMC Proc 8:O6. https://doi.org/10.1186/1753-6561-8-S4-O6

    Article  PubMed Central  Google Scholar 

  26. Chung S, Lin YL, Reed C et al (2014) Characterization of in vitro antibody-dependent cell-mediated cytotoxicity activity of therapeutic antibodies—impact of effector cells. J Immunol Methods. https://doi.org/10.1016/j.jim.2014.03.021

    Article  PubMed  Google Scholar 

  27. Wang W, Erbe AK, Hank JA et al (2015) NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. Front Immunol 6:368

    PubMed  PubMed Central  Google Scholar 

  28. Boyerinas B, Jochems C, Fantini M et al (2015) Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res. https://doi.org/10.1158/2326-6066.CIR-15-0059

    Article  PubMed  PubMed Central  Google Scholar 

  29. Glassman PM, Balthasar JP (2014) Mechanistic considerations for the use of monoclonal antibodies for cancer therapy. Cancer Biol Med. https://doi.org/10.7497/j.issn.2095-3941.2014.01.002

    Article  PubMed  PubMed Central  Google Scholar 

  30. Zhou X, Hu W, Qin X (2008) The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. Oncologist. https://doi.org/10.1634/theoncologist.2008-0089

    Article  PubMed  Google Scholar 

  31. Hallek M (2006) Chemo-immunotherapy—the role of monoclonal antibodies for the treatment of chronic lymphocytic leukaemia. Eur Oncol Dis 1:73–76. https://doi.org/10.17925/EOH.2006.0.2.73

    Article  Google Scholar 

  32. Peddi PF, Hurvitz SA (2014) Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential. Ther Adv Med Oncol 6:202–209

    Article  CAS  Google Scholar 

  33. Weiner LM, Surana R, Wang S (2010) Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 10:317–327

    Article  CAS  Google Scholar 

  34. Scott AM, Allison JP, Wolchok JD (2012) Monoclonal antibodies in cancer therapy. Cancer Immun 12:14

    PubMed  PubMed Central  Google Scholar 

  35. Al-Sawaf O, Fischer K, Engelke A et al (2017) Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy. Drug Des Dev Ther 11:295–304

    Article  CAS  Google Scholar 

  36. Redman JM, Hill EM, AlDeghaither D, Weiner LM (2015) Mechanisms of action of therapeutic antibodies for cancer. Mol Immunol 67:28–45

    Article  CAS  Google Scholar 

  37. Lee JY, Lee HT, Shin W et al (2016) Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy. Nat Commun 7:13354. https://doi.org/10.1038/ncomms13354

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Dhillon S (2015) Dinutuximab: first global approval. Drugs 75:923–927. https://doi.org/10.1007/s40265-015-0399-5

    Article  CAS  PubMed  Google Scholar 

  39. Magen H, Muchtar E (2016) Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment. Ther Adv Hematol 7:187–195. https://doi.org/10.1177/2040620716652862

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Sanchez L, Wang Y, Siegel DS, Wang ML (2016) Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. J Hematol Oncol 9:51. https://doi.org/10.1186/s13045-016-0283-0

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Krishnamurthy A, Jimeno A (2017) Atezolizumab: a novel PD-L1 inhibitor in cancer therapy with a focus in bladder and non-small cell lung cancers. Drugs Today 53:217–237. https://doi.org/10.1358/dot.2017.53.4.2589163

    Article  CAS  PubMed  Google Scholar 

  42. Kaplon H, Reichert JM (2018) Antibodies to watch in 2018. MAbs 10:183–203. https://doi.org/10.1080/19420862.2018.1415671

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Cai HH (2018) Therapeutic monoclonal antibodies approved by FDA in 2017. MOJ Immunol. https://doi.org/10.15406/moji.2017.05.00145

    Article  Google Scholar 

  44. Melosky B, Reardon DA, Nixon AB et al (2018) Bevacizumab biosimilars: scientific justification for extrapolation of indications. Future Oncol. https://doi.org/10.2217/fon-2018-0051

    Article  PubMed  Google Scholar 

  45. Fuenmayor J, Montaño RF (2011) Novel antibody-based proteins for cancer immunotherapy. Cancers 3:3370–3393

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bioengineering Graduate Programme, Institute of Natural & Applied Sciences, Ege University, Izmir, Turkey

    Ilgin Kimiz-Gebologlu & Sultan Gulce-Iz

  2. Department of Bioengineering, Faculty of Engineering, Ege University, Izmir, Turkey

    Sultan Gulce-Iz

  3. Biomedical Technologies Graduate Programme, Institute of Natural & Applied Sciences, Ege University, Izmir, Turkey

    Sultan Gulce-Iz

  4. Department of Medical Biology, Medical School, Ege University, Izmir, Turkey

    Cigir Biray-Avci

Authors
  1. Ilgin Kimiz-Gebologlu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sultan Gulce-Iz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cigir Biray-Avci
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cigir Biray-Avci.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kimiz-Gebologlu, I., Gulce-Iz, S. & Biray-Avci, C. Monoclonal antibodies in cancer immunotherapy. Mol Biol Rep 45, 2935–2940 (2018). https://doi.org/10.1007/s11033-018-4427-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-018-4427-x

Keywords

Search

Navigation